ABSTRACT
The aim of my thesis is to further investigate the mechanisms underlying inflammatory
muscle pain. Despite numerous studies investigating the mechanisms of inflammatory
hyperalgesia, little is known of the mechanisms underlying inflammatory muscle
hyperalgesia. Using rats as experimental animals, I investigated inflammatory hyperalgesia
in muscle and compared it to that of inflamed cutaneous tissue. I injected carrageenan, a
plant-origin polysaccharide, into leg muscle and into the hind paw of rats, and measured
the behavioural response, as well as cytokine changes, in both plasma and inflamed tissue.
Carrageenan induced inflammatory hyperalgesia but the cytokine cascade was not the same
in muscle and cutaneous tissue. At no time following carrageenan injection was muscle
tumour necrosis factor alpha (TNF-&) concentration elevated above that of muscle injected
with saline. TNF-& is a key inflammatory mediator in cutaneous tissue, but apparently not
in muscle. Interleukin-1) (IL-1)) and interleukin-6 concentrations also were different
during muscle inflammation compared to those of cutaneous inflammation. IL-1) and IL-
6 concentrations, following carrageenan injection, were elevated later in muscle compared
to in cutaneous tissue. IL-1) is a potent sensitizer of nociceptors in cutaneous tissue, and
also may play an important role in sustaining muscle pain, but it is unlikely to be an initiator
of the inflammatory muscle hyperalgesia. In the course of comparing muscle hyperalgesia
and cutaneous hyperalgesia, I aimed to identify whether these differences in cytokine
concentrations were unique to muscle tissue or if similar differences in cytokine
concentrations existed between the hind paw and other cutaneous sites. To explore an
alternative cutaneous tissue site, I injected carrageenan into the rat tail and measured the
behavioural response, changes in cytokine concentrations and histological changes.
Elevations of pro-inflammatory cytokines occurred concurrently with the infiltration of leukocytes into the inflamed tail tissue with the thermal and mechanical hyperalgesia similar to that found in the hind paw. Different mechanisms therefore appear to underlie muscle
and cutaneous inflammatory hyperalgesia, regardless of the site used to investigate
cutaneous inflammation. One of the consequences of the poor understanding of muscle
pain is the lack of a reliable regimen for treating human muscle pain, including delayedonset
muscle soreness (DOMS). DOMS, which has a partial inflammatory pathogenesis, is
not relieved by non-selective cyclo-oxygenase inhibitors. This phenomenon may be that
prostaglandins are not produced peripherally or centrally, when muscle tissue is damaged. I
investigated the effect of inhibiting cyclo-oxygenase-2, the isoform released during
inflammation, on DOMS in human volunteers. I found that rofecoxib, a cyclo-oxygenase-2
inhibitor, did not attenuate DOMS and nor did tramadol, a central-acting analgesic. The
neurochemical pathway underlying DOMS therefore appears to be distinct from the
pathways which underlie pain and hyperalgesia in other syndromes. Future research should
include investigations into the central mechanisms of muscle pain and blocking the action
of IL-1) and CINC-1 both peripherally and centrally may prove a beneficial target for the
treatment of clinical muscle pain.
Identifer | oai:union.ndltd.org:netd.ac.za/oai:union.ndltd.org:wits/oai:wiredspace.wits.ac.za:10539/4484 |
Date | 21 February 2008 |
Creators | Loram, Lisa Carole |
Source Sets | South African National ETD Portal |
Language | English |
Detected Language | English |
Type | Thesis |
Format | 8606592 bytes, 35383 bytes, application/pdf, application/pdf, application/pdf, application/pdf |
Page generated in 0.017 seconds